THE EFFECTS OF THE PUTATIVE POTASSIUM CHANNEL ACTIVATOR WAY-120,491 ON RB-86 EFFLUX FROM THE RABBIT AORTA

被引:0
|
作者
LODGE, NJ
COHEN, RB
HAVENS, CN
COLATSKY, TJ
机构
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
WAY-120,491 [(-)-(3S-trans)-2-[3,4-dihydro-3-hydroxy-2,2-dimethyl-6-(triflouromethoxy)-2H-1-benzopyran-4-yl]-2,3-dihydro-1H-isoindol-1-one] is a novel antihypertensive agent. We have investigated the effects of this compound on contractile force and Rb-86 efflux, using the rabbit aorta, in order to assess its K channel activator properties. K channel blockers and ionic conditions thought to modulate specific K channel types have been used to provide insight into the K channel(s) affected by this compound. WAY-120,491 evoked relaxation of precontracted rabbit aortic rings and increased the rate of Rb-86 efflux from strips of rabbit aorta; both effects occurring in a concentration-dependent manner. The WAY-120,491 (1-mu-M)-induced Rb-86 efflux was inhibited by tetraethylammonium (IC50 = 0.38 mM), indicating that the increased efflux was mediated by K channels. Glyburide completely blocked the WAY-120,491 (1-mu-M)-evoked Rb-86 efflux with 50% block occurring at a concentration of 0.48-mu-M. Glyburide also antagonized the WAY-120,491-induced relaxation of aortic rings. Omission of Ca from the solution bathing the aorta did not inhibit the WAY-120,491 induced Rb-86 efflux but rather caused an augmentation of the response. It is concluded that WAY-120,491 may be classified as a K channel opener. Furthermore, the K channel upon which WAY-120,491 acts exhibits some characteristics normally associated with the ATP regulated K channel although the involvement of other K channel types has not been ruled out.
引用
收藏
页码:639 / 644
页数:6
相关论文
共 33 条
  • [1] ELECTROMECHANICAL EFFECTS OF THE PUTATIVE POTASSIUM CHANNEL ACTIVATOR CELIKALIM (WAY-120,491) ON FELINE ATRIAL AND VENTRICULAR MUSCLE
    LODGE, NJ
    COLATSKY, TJ
    CULLINAN, CA
    FOLLMER, CH
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1992, 261 (03): : 1153 - 1159
  • [2] THE SYNTHESIS AND STRUCTURAL CHARACTERIZATION OF WAY-120,491 - A NOVEL POTASSIUM CHANNEL ACTIVATOR
    QUAGLIATO, DA
    HUMBER, LG
    JOSLYN, BL
    SOLL, RM
    BROWNE, ENC
    SHAW, CC
    VANENGEN, D
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1991, 1 (01) : 39 - 42
  • [3] COMPARATIVE EFFECTS OF POTASSIUM CHANNEL OPENERS ON RB-86 EFFLUX FROM RAT ILEUM
    DAVIES, MP
    MCCURRIE, JR
    WOOD, D
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1993, 110 : P130 - P130
  • [4] EFFECTS OF PUTATIVE K+ CHANNEL ACTIVATOR BRL-34915 ON ARTERIAL CONTRACTION AND RB-86 EFFLUX
    COX, RH
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1990, 252 (01): : 51 - 59
  • [5] EFFECTS OF HYDROCHLOROTHIAZIDE ON CONTRACTION AND RB-86 EFFLUX IN RAT AORTA
    WANG, GS
    LI, YS
    FU, SX
    [J]. ACTA PHARMACOLOGICA SINICA, 1993, 14 (05): : 409 - 413
  • [6] POTASSIUM CHANNEL ACTIVATORS CROMAKALIM AND CELIKALIM (WAY-120,491) FAIL TO DECREASE MYOCARDIAL INFARCT SIZE IN THE ANESTHETIZED CANINE
    KITZEN, JM
    MCCALLUM, JD
    HARVEY, C
    MORIN, ME
    OSHIRO, GT
    COLATSKY, TJ
    [J]. PHARMACOLOGY, 1992, 45 (02) : 71 - 82
  • [7] DIFFERENTIAL CALCIUM DEPENDENCE OF CONTRACTILE RESPONSES AND RB-86 EFFLUX FROM THE RABBIT AORTA INDUCED BY VASOACTIVE STIMULI
    MARTIN, W
    GORDON, JL
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1983, 115 (01) : 46 - 52
  • [8] BRL 34915-INDUCED STIMULATION OF RB-86 EFFLUX IN RABBIT AORTA AND ITS DEPENDENCE ON CALCIUM
    KREYE, VAW
    WESTON, AH
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 1986, 374 : P36 - P36
  • [9] DEPOLARIZATION-INDUCED RB-86(+) EFFLUX IN CHO CELLS EXPRESSING A RECOMBINANT POTASSIUM CHANNEL
    HU, W
    TORAL, J
    CERVONI, P
    ZIAI, MR
    SOKOL, PT
    [J]. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1995, 34 (01) : 1 - 7
  • [10] ACTION OF KC-399, A NEWLY SYNTHESIZED POTASSIUM CHANNEL OPENER, ON MECHANICAL-ACTIVITY AND RB-86 EFFLUX IN RAT AORTA
    TAMURA, K
    SUZUKI, Y
    YOSHIDA, S
    NABATA, H
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1994, 23 (02) : 220 - 226